NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 14 min 33 sec ago

Extramural Loan Repayment Program for Pediatric Research (LRP-PR)

Thu, 2022-06-30 10:04
Notice NOT-OD-22-149 from the NIH Guide for Grants and Contracts

Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)

Thu, 2022-06-30 10:04
Notice NOT-OD-22-148 from the NIH Guide for Grants and Contracts

George M. O'Brien Kidney National Resource Centers (U54 - Clinical Trial Not Allowed)

Thu, 2022-06-30 06:15
Funding Opportunity RFA-DK-22-007 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for the George M. OBrien Kidney Consortium --National Resource Centers (NRCs) to lead a nation-wide effort to advance kidney research. The Consortium will consist of ~8 National Resource Centers (NRCs) and one National Coordinating Center (NCC). The NRCs will establish theme-based cores to develop and nationally share unique resources, tools, technologies, services, and expertise, and to support and expand the pool of investigators pursuing kidney research.

National Coordinating Center for the George M. OBrien Kidney National Resource Centers (U24 - Clinical Trial Not Allowed)

Thu, 2022-06-30 06:15
Funding Opportunity RFA-DK-22-008 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for the George M. OBrien Kidney Consortium -- National Coordination Center (NCC) to lead a nation-wide effort to advance kidney research. The OBrien Kidney Consortium will consist of ~8 National Resource Centers (NRCs) tasked with developing and sharing specialized kidney resources tools, technologies, services, and expertise and one NCC to lead, manage, and harmonize all aspects of the Consortium. Specifically, the NCC will: (1) provide administrative support and coordination for the entire Consortium, (2) establish and curate a one-stop-shop sharing portal for the entire Consortium, (3) develop and implement a multipronged communication and education plan to maximize national outreach and impact, (4) ensure that patient viewpoints, priorities, and preferences inform all aspects of the Consortium, and (5) administer and manage a national Opportunity Pool program to address gaps and promote collaboration.

New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)

Thu, 2022-06-30 05:59
Funding Opportunity RFA-ES-22-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to better capture this variability in responses to chemical exposure in the population based on individual genetic susceptibility.

Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only)

Wed, 2022-06-29 12:52
Funding Opportunity RFA-DA-23-018 from the NIH Guide for Grants and Contracts. To ensure that digital therapeutics that have been or are in the development for SUD are adopted, this funding opportunity concept aims to fund clinical trials that will generate convincing data to improve adoption by the payors.

Guidance for Surgeon Effort Level on AHRQ Individual Mentored K Awards

Wed, 2022-06-29 12:34
Notice NOT-HS-22-018 from the NIH Guide for Grants and Contracts

NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)

Wed, 2022-06-29 12:33
Funding Opportunity PAR-22-171 from the NIH Guide for Grants and Contracts. The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.

NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

Tue, 2022-06-28 12:15
Funding Opportunity PAR-22-201 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)

Tue, 2022-06-28 10:33
Funding Opportunity RFA-AR-23-001 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. These Centers promote collaborative basic, translational, and clinical research, and provide important resources that can be used by the national muscular dystrophy research community. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Furthermore, Center investigators participate in community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.

Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)

Tue, 2022-06-28 03:14
Funding Opportunity RFA-TR-22-030 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to solicit applications for pilot projects to elucidate a role for understudied proteins associated with rare diseases. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s).

Commercial Fishing Occupational Safety Research Cooperative Agreement (U01)

Tue, 2022-06-28 02:52
Funding Opportunity RFA-OH-22-005 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to provide funding to individuals in academia, members of non-profit organizations and businesses involved in fishing and maritime matters, and other entities with expertise in commercial fishing safety.

Pages